Burning Rock Biotech Ltd. ADR (BNR) News
Filter BNR News Items
BNR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNR News Highlights
- For BNR, its 30 day story count is now at 4.
- Over the past 20 days, the trend for BNR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ROCK, NGS and ACT are the most mentioned tickers in articles about BNR.
Latest BNR News From Around the Web
Below are the latest news stories about BURNING ROCK BIOTECH LTD that investors may wish to consider to help them evaluate BNR as an investment opportunity.
Burning Rock Announces Results of 2023 Annual General MeetingGUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & You |
Burning Rock Biotech Limited (NASDAQ:BNR) Q3 2023 Earnings Call TranscriptBurning Rock Biotech Limited (NASDAQ:BNR) Q3 2023 Earnings Call Transcript November 30, 2023 Operator: Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation […] |
Q3 2023 Burning Rock Biotech Ltd Earnings CallQ3 2023 Burning Rock Biotech Ltd Earnings Call |
Burning Rock Reports Third Quarter 2023 Financial ResultsGUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Personalized Minimal Residual Disease (MRD) product, brPROPHETTM supports advance |
Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023GUANGZHOU, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 20, 2023 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, |
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023GUANGZHOU, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2023 before the U.S. market opens on November 30, 2023. Following the release, company management will host a conference call at 7:00 a.m. E |
Burning Rock Biotech Limited's (NASDAQ:BNR) largest shareholders are individual investors with 29% ownership, institutions own 26%Key Insights The considerable ownership by individual investors in Burning Rock Biotech indicates that they... |
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion DiagnosticsGUANGZHOU, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese patients with safer, more efficient, and precise treatment options and diagnostic methods, thereby promoting innovation and development in cancer tre |
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection TestGUANGZHOU, China, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China National Medical Products Administration(NMPA), which represents the only |
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer CellGUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826). The MEDAL is a 5-year study that aimed to investigate the clinical utility of MRD in patients with non-small cell lung |